Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce
mortality from ovarian cancer in women aged 55-74 at entry.
I. To assess screening variables, other than mortality, for each of the interventions
including sensitivity, specificity, and positive predictive value.
II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the
mortality predictive value of biologic and/or prognostic characterizations of tumor tissue
as intermediate endpoints.
IV. To conduct biomolecular and genetic research into factors associated with cancer
carcinogenesis and promotion, as well as the early detection of these factors.
OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender,
and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms
(control vs screening).
ARM I (Control): Participants receive standard medical care. Participants complete a Diet
History Questionnaire (DHQ) at baseline.
ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis
at baseline annually for 5 years. Serum that is not used in the study will be stored in an
NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in
December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking
procedure is implemented to ensure regular attendance at repeat screens for participants
screened negative or for those who are designated suspicious or positive at screening but
for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic
procedures are through their own medical care environment). Participants diagnosed with
ovarian cancer via a screening test are referred for treatment in accordance with current
accepted practice for appropriate stage of disease, patient age, and medical condition; a
procedure is provided for contact with qualified medical personnel to insure appropriate
Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual
Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH]
questionnaire) is mailed to each participant annually for 13 years to identify all prevalent
and incident cancers of the ovaries as all deaths that occur among both screened and control
subjects during the trial.
After completion of screening, participants are followed up for at least 13 years.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening
Ovarian cancer-specific mortality rate (including primary peritoneal and fallopian tube cancers)
Event rates defined as the ratio of the number of events (deaths) to the person-years at the risk for the event.
Up to 13 years
Mark O Hatfield-Warren Grant Magnuson Clinical Center
United States: Institutional Review Board
|Mark O Hatfield-Warren Grant Magnuson Clinical Center||Bethesda, Maryland 20892|